Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Ramon

Showing results (111-120 of 147) with videos related to

Pageof 15
Sort By:
The Journal of Urology|September 17, 2004
ErbB2 is a tumor associated antigen and a suitable therapeutic target in Wilms tumorJ H Pinthus, E Fridman, B Dekel, et al.
Heart Rhythm|July 13, 2010
Analysis of temporal delay in myocardial deformation throughout the cardiac cycle: utility for selecting candidates for cardiac resynchronization therapyEtelvino Silva, Marta Sitges, Adelina Doltra, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|July 12, 2020
Bevacizumab in recurrent ovarian cancer: could it be particularly effective in patients with clear cell carcinoma?A Gallego, J Ramon-Patino, J Brenes, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society|April 18, 2025
Gentle and efficient engineering of primary human NK cells by photoporation with polydopamine nanosensitizersC Hinnekens, J Ramon, M Birben, et al.
Prostate Cancer and Prostatic Diseases|November 15, 2006
Bicalutamide (Casodex) 150 mg plus standard care in early non-metastatic prostate cancer: results from Early Prostate Cancer Trial 24 at a median 7 years' follow-upM Wirth, C Tyrrell, K Delaere, et al.
Clinical Oncology (Royal College of Radiologists (Great Britain))|August 9, 2016
Association between the Absolute Baseline Lymphocyte Count and Response to Neoadjuvant Platinum-based Chemotherapy in Muscle-invasive Bladder CancerR Leibowitz-Amit, A Israel, M Gal, et al.
Prostate Cancer and Prostatic Diseases|September 12, 2012
Detection of prostate cancer by radio-frequency near-field spectroscopy in radical prostatectomy ex vivo specimensZ A Dotan, E Fridman, A Lindner, et al.
Prostate Cancer and Prostatic Diseases|June 3, 2005
Bicalutamide ('Casodex') 150 mg in addition to standard care in patients with nonmetastatic prostate cancer: updated results from a randomised double-blind phase III study (median follow-up 5.1 y) in the early prostate cancer programmeM Wirth, C Tyrrell, K Delaere, et al.
Urology|August 8, 2001
Bicalutamide (Casodex) 150 mg as immediate therapy in patients with localized or locally advanced prostate cancer significantly reduces the risk of disease progressionM Wirth, C Tyrrell, M Wallace, et al.
The Prostate|April 4, 2008
Clinical assessment of the cancer diagnostic value of prostatic zinc: a comprehensive needle-biopsy studyM Cortesi, E Fridman, A Volkov, et al.
Pageof 15

Showing results (111-120 of 147) with videos related to

Sort By:
Pageof 15
The Journal of Urology|September 17, 2004
ErbB2 is a tumor associated antigen and a suitable therapeutic target in Wilms tumorJ H Pinthus, E Fridman, B Dekel, et al.
Heart Rhythm|July 13, 2010
Analysis of temporal delay in myocardial deformation throughout the cardiac cycle: utility for selecting candidates for cardiac resynchronization therapyEtelvino Silva, Marta Sitges, Adelina Doltra, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|July 12, 2020
Bevacizumab in recurrent ovarian cancer: could it be particularly effective in patients with clear cell carcinoma?A Gallego, J Ramon-Patino, J Brenes, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society|April 18, 2025
Gentle and efficient engineering of primary human NK cells by photoporation with polydopamine nanosensitizersC Hinnekens, J Ramon, M Birben, et al.
Prostate Cancer and Prostatic Diseases|November 15, 2006
Bicalutamide (Casodex) 150 mg plus standard care in early non-metastatic prostate cancer: results from Early Prostate Cancer Trial 24 at a median 7 years' follow-upM Wirth, C Tyrrell, K Delaere, et al.
Clinical Oncology (Royal College of Radiologists (Great Britain))|August 9, 2016
Association between the Absolute Baseline Lymphocyte Count and Response to Neoadjuvant Platinum-based Chemotherapy in Muscle-invasive Bladder CancerR Leibowitz-Amit, A Israel, M Gal, et al.
Prostate Cancer and Prostatic Diseases|September 12, 2012
Detection of prostate cancer by radio-frequency near-field spectroscopy in radical prostatectomy ex vivo specimensZ A Dotan, E Fridman, A Lindner, et al.
Prostate Cancer and Prostatic Diseases|June 3, 2005
Bicalutamide ('Casodex') 150 mg in addition to standard care in patients with nonmetastatic prostate cancer: updated results from a randomised double-blind phase III study (median follow-up 5.1 y) in the early prostate cancer programmeM Wirth, C Tyrrell, K Delaere, et al.
Urology|August 8, 2001
Bicalutamide (Casodex) 150 mg as immediate therapy in patients with localized or locally advanced prostate cancer significantly reduces the risk of disease progressionM Wirth, C Tyrrell, M Wallace, et al.
The Prostate|April 4, 2008
Clinical assessment of the cancer diagnostic value of prostatic zinc: a comprehensive needle-biopsy studyM Cortesi, E Fridman, A Volkov, et al.
Pageof 15